Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 2/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 11/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL568026 | 1.00 | PDPK1 (0.46) | PDPK1CDK1CDK2TYRATM | |
| SCHEMBL11130951 | 0.83 | SLC5A2 (0.43) | ATMSLC5A1SLC5A2ALDH1A1POLB | |
| SCHEMBL8068087 | 0.83 | CDK1 (0.47) | CDK1CDK2 | |
| SCHEMBL2941560 | 0.83 | ALDH1A1 (0.41) | TYRATMSLC5A1SLC5A2ALDH1A1 | |
| SCHEMBL11011378 | 0.83 | FBP1 (0.45) | PDPK1CDK1CDK2 | |
| Ribose (Furanose) SCHEMBL291402 | 0.82 | PDPK1 (0.61) | PDPK1CDK1CDK2CDC7DBF4 | |
| SCHEMBL8059232 | 0.82 | CDK1 (0.46) | CDK1CDK2 | |
| SCHEMBL11133877 | 0.81 | SLC5A2 (0.44) | TYRATMSLC5A1SLC5A2ALDH1A1 | |
| SCHEMBL1963526 | 0.76 | PDPK1 (0.46) | PDPK1ALDH1A1 | |
| Ribose (Furanose) SCHEMBL12542065 | 0.75 | HSD17B10 (0.40) | PDPK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233857-A1 | BIOACTIVE COMPOUNDS OBTAINED FROM CYANOBACTERA LEPTOTHOE SP. LEGE 181152 | CIIMAR - Centro Interdisciplinar de Investigação Marinha e Ambiental (PT) | 2023-08-30 | — | — | EP | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| JP-58052223-A | — | — | None | — | — | JP | disclosed |
| JP-54092695-A | — | — | None | — | — | JP | disclosed |
| JP-55013010-A | — | — | None | — | — | JP | disclosed |
| CN-122081247-A | Oncolytic vaccinia virus and recombinant viruses and methods of use thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260137773-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260097116-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12419924-B2 | Methods for combining adoptive T cell therapy with oncolytic virus adjunct therapy | TVAX BIOMEDICAL I, LLC (US) | 2025-09-23 | — | — | US | disclosed |
| US-12338464-B2 | Clonal strains of attenuated vaccinia viruses and methods of use thereof | GENELUX CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4551240-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | Viromissile, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
| JP-S5852223-A | DEAMINASE INHIBITOR | AJINOMOTO CO INC | 1983-03-28 | — | — | JP | disclosed |
| US-4371613-A | TRANSARABINOSYLATION USING AN ENZYME FROM BACTERIA, AN ARABINOSE DONOR AND A PURINE SOURCE | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-02-01 | — | — | US | disclosed |
| JP-S5513010-A | PREPARATION OF PURINE ARABINOSIDE | AJINOMOTO CO INC | 1980-01-29 | — | — | JP | disclosed |
| JP-S5492695-A | 2-SUBSTITUTED HYPOXANTHINEARABINOSIDE AND ITS PREPARATION | AJINOMOTO CO INC | 1979-07-23 | — | — | JP | disclosed |
| JP-S05492695-A | — | — | 0001-01-01 | — | — | JP | disclosed |
| JP-S05513010-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | PDPK1 3616/4885CDK1 1589/4885CDK2 857/4885 |
| US-20260097116-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | IRF3, IFNAR1, CXCL10 | PDPK1 3922/4885CDK1 2347/4885CDK2 2033/4885 |
| US-20260137773-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | CASP9, TP53, CASP2 | PDPK1 2402/4885CDK1 1528/4885CDK2 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.